Heidelberg, Germany, May 10, 2017 - Affimed N.V. (Nasdaq: AFMD) today announced that on May 17, 2017, the Company will release its financial results for the quarter ended March 31, 2017. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Wednesday, May 17, 2017 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 7342202.
|Local - Amsterdam, the Netherlands:||+31 (0) 20 716 8257|
|Local - Copenhagen, Denmark:||+45 38 32 28 69|
|Local - Frankfurt, Germany:||+49 (0) 69 2222 10620|
|Local - Geneva, Switzerland:||+41 (0) 22 592 7953|
|Local - London, U.K.:||+44 (0) 20 3427 1919|
|Local - New York City, U.S.A.:||+1 646 254 3361|
|Local - Paris, France:||+33 (0) 1 76 77 22 25|
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: IR@affimed.com or firstname.lastname@example.org
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341